Literature DB >> 19482678

Chemokines and B cells in renal inflammation and allograft rejection.

Oliver M Steinmetz1, Rolf A K Stahl, Ulf Panzer.   

Abstract

Recently the presence of intrarenal B cells in various inflammatory kidney diseases has been described and was in some cases linked to an unfavourable clinical course. Mechanisms leading to B cell influx into the kidney have therefore gained interest. Available data from the literature will be reviewed here with special focus on the contribution of chemokines. By far the most data from animal studies and human biopsies exist for BCA-1/CXCL13 pointing to a central role for this chemokine in B cell trafficking via interaction with its corresponding receptor CXCR5 on the B cell surface. Future studies will help to improve the knowledge on functional importance of B cell attracting chemokines as well as clinical significance of intrarenal B cell infiltrates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19482678     DOI: 10.2741/S2

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  9 in total

1.  CXCL10 and CXCL13 Expression were highly up-regulated in peripheral blood mononuclear cells in acute rejection and poor response to anti-rejection therapy.

Authors:  Youying Mao; Minmin Wang; Qin Zhou; Juan Jin; Yucheng Wang; Wenhan Peng; Jianyong Wu; Zhangfei Shou; Jianghua Chen
Journal:  J Clin Immunol       Date:  2010-12-30       Impact factor: 8.317

2.  Preserving the B-cell compartment favors operational tolerance in human renal transplantation.

Authors:  Hernandez M Silva; Maisa C S Takenaka; Pedro M M Moraes-Vieira; Sandra M Monteiro; Maristela O Hernandez; Wahiba Chaara; Adrien Six; Fabiana Agena; Patrícia Sesterheim; Florencia Maria Barbé-Tuana; David Saitovitch; Francine Lemos; Jorge Kalil; Verônica Coelho
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

3.  Stat3 programs Th17-specific regulatory T cells to control GN.

Authors:  Malte A Kluger; Michael Luig; Claudia Wegscheid; Boeren Goerke; Hans-Joachim Paust; Silke R Brix; Isabell Yan; Hans-Willi Mittrücker; Beate Hagl; Ellen D Renner; Gisa Tiegs; Thorsten Wiech; Rolf A K Stahl; Ulf Panzer; Oliver M Steinmetz
Journal:  J Am Soc Nephrol       Date:  2014-02-07       Impact factor: 10.121

4.  Urinary CXCL9 and CXCL10 Levels and Acute Renal Graft Rejection.

Authors:  H S Ciftci; T Tefik; M K Savran; E Demir; Y Caliskan; Y D Ogret; T Oktar; O Sanlı; T Kocak; Y Ozluk; F S Oguz; I Kilicaslan; F Aydın; A Turkmen; I Nane
Journal:  Int J Organ Transplant Med       Date:  2019-05-01

5.  Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing.

Authors:  Hans-Joachim Anders
Journal:  Organogenesis       Date:  2012-04-01       Impact factor: 2.500

6.  Lymphotoxin expression in human and murine renal allografts.

Authors:  Harald Seeger; Maja T Lindenmeyer; Clemens D Cohen; Carsten Jaeckel; Peter J Nelson; Jin Chen; Ilka Edenhofer; Nicolas Kozakowski; Heinz Regele; Georg Boehmig; Simone Brandt; Rudolf P Wuethrich; Mathias Heikenwalder; Thomas Fehr; Stephan Segerer
Journal:  PLoS One       Date:  2018-01-04       Impact factor: 3.240

7.  Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.

Authors:  Keizo Takenaga; Miho Akimoto; Nobuko Koshikawa; Hiroki Nagase
Journal:  PLoS One       Date:  2020-04-27       Impact factor: 3.240

8.  Elevated Circulating IL-10 Producing Breg, but Not Regulatory B Cell Levels, Restrain Antibody-Mediated Rejection After Kidney Transplantation.

Authors:  Yongsheng Luo; Feifei Luo; Kuanxin Zhang; Shilei Wang; Haojie Zhang; Xianlei Yang; Wenjun Shang; Junxiang Wang; Zhigang Wang; Xinlu Pang; Yonghua Feng; Lei Liu; Hongchang Xie; Guiwen Feng; Jinfeng Li
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

Review 9.  Danger control programs cause tissue injury and remodeling.

Authors:  Jan H Hagemann; Holger Haegele; Susanna Müller; Hans-Joachim Anders
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.